

****Pharmacy Notice****

**Louisiana Department of Health Bureau of Health Services
Financing (Louisiana Medicaid)**

BIN 025986 PCN 1214172240

*******Important Notice of Reimbursement*******

340B Carve-In Pharmacy Notification

Prime Therapeutics accepts the use of DAW 5 (*Substitution Allowed – Brand Drug Dispensed as Generic*) present on 340B carve-in pharmacy claims when the brand drug is less expensive than the generic drug for 340B carve-in pharmacy providers, as described in the Louisiana Single Pharmacy Benefit Manager for Managed Care Program – Provider Manual.

Claims from 340-B pharmacies submitted with DAW-5 present on the claim will be reimbursed as a generic medication. These claims are currently reimbursed at the brand rate. This change will be implemented on August 18, 2025.

All other 340B Program requirements described in the Prime Provider Manual and in Louisiana Department of Health (LDH) policies continue to apply, including the use appropriate Submission Clarification Codes (SCC).

If you have questions about this notice, call Prime at 888.277.5510, option 1. You can also email your question to ProviderRelations@primetherapeutics.com and reference LA MCO 340-B DAW-5 reimbursement.